New FreVAX™ smartphone application brings piglet vaccination to another level

• Easy management of vaccination events including date, location, pig group and age, dose, vaccines used, and caregiver associated with actual vaccination sessions compliance
• Advanced device usage interface with self-diagnostics and multiple languages settings
• Improved support with access to online helpdesk, FAQs and return process if needed
• Export of consistent vaccination reports with high data quality

• The FreVAX™ device is currently being commercialized in 31 countries around the world
• The device transfers the vaccination data to the new smartphone app allowing a remote and real-time data analysis including detailed vaccination session reports
• Around 500 FreVAX™ devices have been shipped to various countries in 2021
   

“There is no doubt about increasing interest in needle free devices due to the added benefits regarding pig safety and welfare leading to improved meat quality. At the same time veterinarians and progressive swine producers are looking for convenient and reliable tools in the farm with a big focus on the vaccination process,” commented Dr. Markus Hammer, Global Head of Swine at Boehringer Ingelheim Animal Health. “We now have an offering that incorporates an accurate, safe, needle free  intramuscular administration method with the new FreVAX™ app 2.0 to provide  improved  vaccination compliance and data management,” added Marius Leyhausen, Senior Global Brand Manager, Integrated Health Management at Boehringer Ingelheim Animal Health.

More information:

¹ www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-henke-sass-wolf-develop-needle-free-device
www.frevax.com

Boehringer Ingelheim Animal Health

The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 9,700 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.

Respect for animals, humans and the environment is at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases.

Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of 4.1 billion euros in 2020 and presence in more than 150 countries. For more information visit: www.boehringer-ingelheim.com/animal-health/overview.

Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com.

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business